untitled
<OAI-PMH schemaLocation=http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd>
<responseDate>2018-01-15T18:22:50Z</responseDate>
<request identifier=oai:HAL:hal-01334073v1 verb=GetRecord metadataPrefix=oai_dc>http://api.archives-ouvertes.fr/oai/hal/</request>
<GetRecord>
<record>
<header>
<identifier>oai:HAL:hal-01334073v1</identifier>
<datestamp>2018-01-10</datestamp>
<setSpec>type:ART</setSpec>
<setSpec>subject:sdv</setSpec>
<setSpec>collection:UNIV-RENNES1</setSpec>
<setSpec>collection:UNIV-AG</setSpec>
<setSpec>collection:UNIV-PARIS7</setSpec>
<setSpec>collection:U823</setSpec>
<setSpec>collection:IRSET</setSpec>
<setSpec>collection:APHP</setSpec>
<setSpec>collection:UNIV-PARIS5</setSpec>
<setSpec>collection:UNIV-GRENOBLE1</setSpec>
<setSpec>collection:IFR140</setSpec>
<setSpec>collection:UNIV-PARIS13</setSpec>
<setSpec>collection:BIOSIT</setSpec>
<setSpec>collection:UR1-UFR-SVE</setSpec>
<setSpec>collection:UR1-HAL</setSpec>
<setSpec>collection:UGA</setSpec>
<setSpec>collection:USPC</setSpec>
<setSpec>collection:EHESP</setSpec>
<setSpec>collection:STATS-UR1</setSpec>
<setSpec>collection:UR1-SDV</setSpec>
<setSpec>collection:IRSET-2</setSpec>
<setSpec>collection:UNIV-ANGERS</setSpec>
<setSpec>collection:IAME</setSpec>
<setSpec>collection:INRA</setSpec>
</header>
<metadata><dc>
<publisher>HAL CCSD</publisher>
<title lang=en>Antifungal De-Escalation Is Safe in Critically Ill Patients Treated For Suspected Or Documented Invasive Candidiasis. Data From The Amarcand2 Study</title>
<creator>Bailly, S.</creator>
<creator>Leroy, O.</creator>
<creator>Montravers, P.</creator>
<creator>Constantin, J. M.</creator>
<creator>Dupont, H.</creator>
<creator>Guillemot, D.</creator>
<creator>Lortholary, O.</creator>
<creator>Mira, J. P.</creator>
<creator>Perrigault, P. F.</creator>
<creator>Gangneux, J. P.</creator>
<creator>Azoulay, E.</creator>
<creator>Timsit, J. F</creator>
<contributor>Infection, Antimicrobiens, Modélisation, Evolution (IAME) ; Université Paris 13 (UP13) - Université Paris Diderot - Paris 7 (UPD7) - Université Sorbonne Paris Cité (USPC) - Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<contributor>Institut de Biologie et Pathologie ; CHU Grenoble</contributor>
<contributor>Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823) ; Université Joseph Fourier - Grenoble 1 (UJF) - CHU Grenoble - EFS - Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<contributor>Service Réanimation Adultes ; Centre Hospitalier Universitaire de Clermont-Ferrand</contributor>
<contributor>Centre d’Infectiologie Necker Pasteur ; CHU Necker - Enfants Malades [AP-HP] - Université Paris Descartes - Paris 5 (UPD5) - Assistance publique - Hôpitaux de Paris (AP-HP)</contributor>
<contributor>Institut de recherche, santé, environnement et travail [Rennes] (Irset) ; Université d'Angers (UA) - Université des Antilles et de la Guyane (UAG) - Université de Rennes 1 (UR1) - École des Hautes Études en Santé Publique [EHESP] (EHESP) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )</contributor>
<contributor>Service de Réanimation Médicale, Hôpital Saint Louis, Paris, France ; Service de Réanimation Médicale, Hôpital Saint Louis, Paris, France</contributor>
<contributor>Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A 1125)) ; Institut National de la Recherche Agronomique (INRA) - Université Sorbonne Paris Cité (USPC) - Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<description>International audience</description>
<source>Intensive Care Medicine Experimental</source>
<identifier>hal-01334073</identifier>
<identifier>https://hal-univ-rennes1.archives-ouvertes.fr/hal-01334073</identifier>
<source>https://hal-univ-rennes1.archives-ouvertes.fr/hal-01334073</source>
<source>Intensive Care Medicine Experimental, 2015, 3 (Suppl 1), pp.A5. 〈10.1186/2197-425X-3-S1-A5〉</source>
<identifier>DOI : 10.1186/2197-425X-3-S1-A5</identifier>
<relation>info:eu-repo/semantics/altIdentifier/doi/10.1186/2197-425X-3-S1-A5</relation>
<identifier>PUBMED : 27290057</identifier>
<relation>info:eu-repo/semantics/altIdentifier/pmid/27290057</relation>
<language>en</language>
<subject>[SDV] Life Sciences [q-bio]</subject>
<type>info:eu-repo/semantics/article</type>
<type>Journal articles</type>
<description lang=en>Systemic Antifungal therapy (SAT) of invasive candidiasis (IC) needs to be started immediately upon clinical suspicion. Controversies exist then about potential harms from antifungal de-escalation (DE).(1) in cases of documented IC, early DE to fluconazole is recommended by US guidelines but discouraged in EU guidelines. in non-documented IC, no data are available to guide SAT DE. These questions are key issues however as the relationship between antifungal use and Candida antifungal resistance has been repeatedly demonstrated.</description>
<date>2015-12</date>
</dc>
</metadata>
</record>
</GetRecord>
</OAI-PMH>
